Regulatory Resources Group sold to Voisin Consulting Life Sciences
BCMS has advised the shareholders of Regulatory Resources Group (RRG) – an independent regulatory consultancy for the pharmaceutical industry – on the sale of the business to Voisin Consulting Life Sciences (VCSL).
At the time of the transaction, RRG was one of the longest established independent consultancies in Europe. Based in Camberley, UK, the firm provided an extensive range of regulatory and development services for drug products, medical devices and drug-device combinations in several therapeutic areas, with significant regulatory, clinical, non-clinical and chemistry, manufacturing and control (CMC) expertise.
RRG specialised in all aspects of European and US regulatory affairs
Working with a global client base, RRG specialised in management of the entire regulatory process from authoring and reviewing submission documents to submission compilation and liaison with regulatory authorities. Core to RRG’s offering was its tailored training solutions to its clients’ regulatory, clinical and quality departments, covering all aspects of European and US regulatory affairs.
RRG demonstrated an impressive track record of successful submissions for clinical trials and marketing authorisations in pharmaceuticals, advanced therapies, biotechnology, devices and other medical technology products, covering all types of European submissions as well as Investigational New Drug (IND) and New Drug Application (NDA) submissions to the FDA.
The acquirer, VCLS, is a global regulatory science and clinical consultancy firm, which guides biotechnology, pharmaceutical and MedTech manufacturers throughout product development and market access. Founded in 1997, VCLS specialises in a range of disciplines, including Health Economic and Outcomes Research (HEOR), clinical operations, medical writing, publishing & submissions, clinical safety and pharmacovigilance.
With a presence in North America, Europe and Southeast Asia, VCLS designs global strategies and adapts execution in each market – accounting for local medical practices, regulatory frameworks and reimbursement landscapes. The business employs over 200 life sciences professionals, offering integrated solutions for development planning, manufacturing, quality and control, nonclinical and clinical testing, safety monitoring, and interactions with regulators and payers.
